IKT
Inhibikase Therapeutics Inc
NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY
$1.93
-0.52% today
Updated 2026-05-05
Market cap
$254.82M
P/E ratio
—
P/S ratio
10.39x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Inhibikase Therapeutics Inc (IKT) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-29573.00 | $-126391.00 | $714987.00 | $-338290.00 | $-1.13M | $-14.30M | $-17.35M | $-18.09M | $-19.15M | $-27.79M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $243255.00 | $14238.00 | $0.00 | $13396.00 |
| Depreciation | — | — | — | — | — | $0.00 | $6723.00 | $177398.00 | $26272.00 | — |
| Stock-based comp | $310088.00 | $300659.00 | $642231.00 | $1.44M | $573695.00 | $1.53M | $458147.00 | $500148.00 | $8.14M | $15.31M |
| Free cash flow | $-29573.00 | $-126391.00 | $714987.00 | $-338290.00 | $-1.13M | $-14.30M | $-17.59M | $-18.10M | $-19.15M | $-27.80M |
| Investing cash flow | $87097.00 | $87097.00 | $87097.00 | — | — | — | — | $11.66M | $-37.00M | — |
| Financing cash flow | $-23769.00 | $131020.00 | $-439192.00 | $-22810.00 | $15.06M | $41.09M | $-204769.00 | $8.41M | $103.48M | — |
| Dividends paid | — | — | — | — | — | $77652.00 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — |